AzTrials
AzTrials

Rheumatoid ArthritisPhase 2NCT02983227

A Study to Evaluate the Long-Term Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Rheumatoid Arthritis Enrolled in Study GA29350

A Phase 2 study testing GDC-0853 in people with Rheumatoid Arthritis, run by Genentech, Inc. at 104 sites in 10 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

A study to evaluate the long-term safety and efficacy of GDC-0853 in participants with moderate to severe active Rheumatoid Arthritis (RA) who have completed 12 weeks of study treatment in Study GA29350. Read more about this study

Who is it for?
Ages 18 to 76 years
Conditions the study is for
Rheumatoid Arthritis
What is being tested?
GDC-0853
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
496 participants
Where
104 sitesin 10 countries
Study dates
30 Nov 2016to 17 Jul 2019
Phase
Phase 2
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 76 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Completion of treatment as specified in Study GA29350, including completion of the Day 84 study visit assessments
  • Acceptable safety and tolerability during Study GA29350 as determined by the investigator or Medical Monitor
  • Have not received any prohibited medications in Study GA29350
  • While taking methotrexate, must be willing to receive oral folic acid (at least 5 milligrams per week [mg/week])
  • If receiving oral corticosteroids (less than or equal to [</=] 10 milligrams per day [mg/day] prednisone or equivalent) and/or non-steroidal anti-inflammatory drugs, doses have remained stable for the duration of Study GA29350

Who cannot join

  • Met protocol defined treatment stopping criteria during Study GA29350
  • Treatment with any investigational agent (i.e., other than study drug) or live/attenuated vaccine or any other prohibited medication during Study GA29350 or since the last administration of study drug in Study GA29350
  • In the opinion of the investigator, any new (since initially enrolling in the Phase II Study GA29350), significant, uncontrolled comorbidity that would increase the risk to the participant in Study GA30067
  • Pregnant or lactating, or intending to become pregnant during the study
  • Participants who experienced a de novo or reactivated serious viral infection such as hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV) during the Phase II Study GA29350
  • Any major episode of infection requiring hospitalization or treatment with intravenous antibiotics during the Phase II Study GA29350
Show all 9Show fewer
  • Participants who developed a malignancy during the Phase II Study GA29350
  • 12-lead electrocardiogram (ECG) on Day 84 in Study GA29350 that demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study results
  • Current treatment with medications that are well known to prolong the QT interval

Trial locations and contacts

104 sites in 10 countries.

104 sites in 10 countries

Ukraine21 sites
  • Railway Transp DCH of HealthCenter Branch of PJSC Ukr Railway Dept of Rheumatology

    Dnipro, Tavria Okruha, 49008

  • Regional CH Dep of Rheumatology SHEI Ivano-Frankivsk NMU

    Ivano-Frankivsk, KIEV Governorate, 76008

  • CI of Healthcare Kharkiv CCH #8 Dept of Therapy Kharkiv MA of PGE of MOHU

    Kharkiv, Kharkiv Governorate, 61176

  • GI L.T.Malaya Therapy National Institute of the NAMS of Ukraine

    Kharkiv, 61039

  • MI of Healthcare Kyiv RCH P.L. Shupyk NMA of PGE

    Kyiv, Chernihiv Governorate, 01601

  • SI NSС M.D. Strazhesko Institute of Cardiology of NAMSU

    Kyiv, KIEV Governorate, 03680

  • Medical Center of Revmotsentr LLC

    Kyiv, KIEV Governorate, 04070

  • Medical Center of Limited Liability Company Medical Clinic Blagomed

    Kyiv, KIEV Governorate, 1023

  • Med Center of International Institute of Clinical Trials LLC; Medical Center "OK!Clinic+"

    Kyiv, KIEV Governorate, 2091

  • CNI Consultative and Diagnostic Center of Desnianskyi District of Kyiv

    Kyiv, 02232

  • CI Lutsk CCH Volyn Regional Center of Cardiovascular Pathology and Thrombolysis

    Lutsk, Volhynian Governorate, 43024

  • Lviv Regional Clinical Hospital Dept of Rehmuaatology D. Halytskyi Lviv NMU

    Lviv, KIEV Governorate, 79010

  • CH of State Border Service of Ukraine (Military Base 2522); Dept of Therapy, D.Halytskyi Lviv NMU

    Lviv, KIEV Governorate, 79014

  • M.V. Sklifosovsky Poltava RCH Dept of Rheumatology HSEIU UMSA

    Poltava, 36011

  • CI of TRC

    Ternopil, Kherson Governorate, 46002

  • A.Novak Transcarpathian Regional Clinical Hospital

    Uzhhorod, KIEV Governorate, 88018

  • National Pirogov Memorial Medical University

    Vinnytsia, Podolia Governorate, 21018

  • City Clinical Hospital #9 Dept of Therapy SI Zaporizhzhia MA of PGE of MoHU

    Zaporizhzhya, Tavria Okruha, 69065

  • CI City Hospital #1

    Zaporizhzhya, Tavria Okruha, 69104

  • CI City Hospital #7

    Zaporizhzhya, 69118

  • CI Zaporizhzhia Regional Clinical Hospital of ZRC

    Zaporizhzhya, 69600

Other trials in Ukraine

Russia19 sites
  • SMMIH "Chelyabinsk Regional Clinical Hospital"

    Chelyabinsk, Voronez, 454076

  • SAHI of Kem. "Regional Clinical Hospital for War Veterans"

    Kemerovo, 650000

  • OOO Family Polyclinic

    Korolev, Moscow Region, 141060

  • Federal State Budgetary Scientific Institution Research Institute of Rheumatology V.A. Nasonova

    Moscow, Moscow Oblast, 115522

  • SBIH of Moscow "City Clinical Hospital # 1 n. a. N. I. Pirogov"

    Moscow, Moscow Oblast, 119049

  • Practical Medicine

    Moscow, 115404

  • Limited Liability Company "Centre of Medical Common Practice"

    Novosibirsk, 630091

  • Ultramed

    Omsk, 644024

  • SPb SBIH "Clinical Rheumatological Hospital # 25"

    Saint Petersburg, Sankt-Peterburg, 190068

  • Sanavita LLC

    Saint Petersburg, Sankt-Peterburg, 195257

  • LLC Medical Sanitary Unit

    Saint Petersburg, Sankt-Peterburg, 196066

  • SEIHPE Saratov State Medical University n.a. V.I. Razumovskiy

    Saratov, 410012

  • NIH "Departmental Hospital on Station Smolensk of OJSC "Russian Railways"

    Smolensk, 214025

  • Siberian State Medical University

    Tomsk, 634050

  • SHI Ulyanovsk Reg Clinical Hospital

    Ulyanovsk, 432063

  • Territorial Clinical Hospital #2

    Vladivostok, 690035

  • SBHI of Yaroslavl Region Clinical Hospital #3

    Yaroslavl, Volgograd Oblast, 150051

  • SBIH of Yaroslavl region " Regional Clinical Hospital "; Therapy

    Yaroslavl, Yaroslavl Oblast, 150062

  • Center of Family Medicine LC

    Yekaterinburg, Sankt-Peterburg, 620043

Other trials in Russia

United States11 sites
  • RASF-Clinical Research Center

    Boca Raton, Florida, 33486

  • Clinical Research of West Florida

    Clearwater, Florida, 33765

  • Medvin Clinical Research

    Covina, California, 91723

  • Metroplex Clinical Research Centre

    Dallas, Texas, 75231

  • Baylor Research Inst.

    Dallas, Texas, 75246

  • TriWest Research Associates, LLC

    El Cajon, California, 92020

  • Saint Jude Heritage Medical Grp

    Fullerton, California, 92835

  • Arizona Arthritis & Rheumatology Associates, P.C.

    Glendale, Arizona, 85306

  • Medication Management

    Greensboro, North Carolina, 27408

  • Accurate Clinical Research

    Houston, Texas, 77089

  • Oregon Health & Science Uni

    Portland, Oregon, 97239

Other trials in United States

Argentina11 sites
  • Instituto de Investigaciones Clinicas-Mar del Plata

    Buenos Aires, B7600FZN

  • APRILLUS

    Buenos Aires, C1194AAO

  • Instituto centenario

    Buenos Aires, C1204AAD

  • Centro de Investigacion en Enfermedades Reumaticas CIER

    Ciudad Autonoma Buenos Aires, C1055AAF

  • Expertia S.A- Mautalen Salud e Investigación

    Ciudad Autonoma Buenos Aires, C1128AAE

  • CCBR - Buenos Aires - AR; AxisMed SRL

    Ciudad Autonoma Buenos Aires, C1430CKE

  • ILAIM-CEOM Inst. Latinoamericano de Inv. Medicas

    Córdoba, X5000BNB

  • Centro de Investigaciones Medicas Mar Del Plata

    Mar del Plata, B7600DHK

  • Instituto de Investigaciones Clinicas

    Rosario, S2000CVD

  • CER San Juan Centro Polivalente de Asistencia e Investigacion Clinica

    San Juan, 5400

  • Centro Medico Privado de Reumatologia; Reumathology

    San Miguel, T4000AXL

Other trials in Argentina

Bulgaria9 sites
  • MHAT "Eurohospital" - Plovdiv, OOD; Internal Department

    Plovdiv, 4002

  • UMHAT "Kaspela", EOOD

    Plovdiv, 4002

  • Medizinski Zentrar-1-Sevlievo EOOD

    Sevlievo, 5400

  • MHAT "Hadzhi Dimitar", OOD

    Sliven, 8800

  • Medical Center Excelsior OOD

    Sofia, 1000

  • NMTH "Tsar Boris III"

    Sofia, 1233

  • DCC "Alexandrovska", EOOD; Clinic of Neurology

    Sofia, 1431

  • MC "Synexus - Sofia", EOOD

    Sofia, 1784

  • UMHAT "SofiaMed", OOD; Department of Neurology

    Sofia, 1797

Other trials in Bulgaria

Mexico9 sites
  • Consultorio Medico en Fundacion el Hospitalito de morelos A.C.

    Cuernavaca, Morelos, 62170

  • Consultorio Particular del Dr. Miguel Cortes Hernandez

    Cuernavaca, 62290

  • Centro de Investigacion de Tratam Innovadores de Sin SC

    Culiacán, 80230

  • Centro de Investigacion en Reumatologia

    Mérida, Yucatán, 97070

  • Centro de Investigacion en Enfermedades Reumaticas y Osteoporosis

    Mexicali, 21100

  • Centro de Investigacion Clínica GRAMEL S.C

    México, 03720

  • Policlinica Medica de Queretaro S.C.

    Querétaro, 76000

  • Clinical Research Institute

    Tlalnepantla, 54055

  • Unidad de Enfermedades Reumaticas y Cronicodegenerativas

    Torreón, 27000

Other trials in Mexico

Poland9 sites
  • NZOZ ZDROWIE Osteo-Medic

    Bialystok, 15-351

  • Szpital Uniwersytecki; nr 2 im. Dr J. Biziela

    Bydgoszcz, 85-168

  • Centrum Medyczne Pratia Katowice I

    Katowice, 40-081

  • CCBR - Lodz - PL

    Lodz, 90-368

  • ETYKA Osrodek Badan Kliniczynch

    Olsztyn, 10-117

  • Ai Centrum Medyczne Sp. Z O.O Sp.K.

    Poznan, 61-113

  • Medycyna Kliniczna

    Warsaw, 00-660

  • Centrum Medyczne AMED

    Warsaw, 03-291

  • KO-MED Centra Kliniczne Zamosc

    Zamość, 22400

Other trials in Poland

Brazil7 sites
  • CAEP - Centro Avancado de Estudos e Pesquisas Ltda.

    Campinas, São Paulo, 13087-567

  • Centro de Estudos em Terapias Inovadoras - CETI

    Curtiba, Paraná, 80030-110

  • CIP - Centro Internacional de Pesquisa X; Pesquisa Clinica

    Goiânia, Goiás, 74110-120

  • CMiP - Centro Mineiro de Pesquisa*X*

    Juiz de Fora, Minas Gerais, 36010-570

  • LMK Serviços Médicos S/S

    Porto Alegre, Rio Grande do Sul, 90480-000

  • CCBR Brasil Centro de Pesquisas e Análises Clínicas Ltda.

    Rio de Janeiro, Rio de Janeiro, 21941-913

  • IMA Brasil - Instituto de Medicina Avancada

    São Paulo, São Paulo, 05437-000

Other trials in Brazil

Serbia5 sites
  • Institute of Rheumatology

    Belgrade, 11000

  • Clinical Center Kragujevac

    Kragujevac, 34000

  • Institute of Treatment and Rehabilitation "Niska Banja"

    Niška Banja, 18205

  • Special hospital for rheumatic diseases Novi Sad

    Novi Sad, 21000

  • General Hospital "Dr Laza K. Lazarevic" Sabac

    Šabac, 15000

Other trials in Serbia

Colombia3 sites
  • Centro de Investigacion Medico Asistencial S.A.S

    Barranquilla, 80020

  • Centro de Investigacion en Reumatologia y Especialdades Medicas SAS. CIREEM

    Bogotá, 110221

  • Riesgo de Fractura S.A.

    Bogotá, 110221

Other trials in Colombia

About this study

Official title: A Phase II Open-Label Extension Study of Patients Previously Enrolled in Study GA29350 to Evaluate the Long-Term Safety and Efficacy of GDC-0853 in Patients With Moderate to Severe Rheumatoid Arthritis

A study to evaluate the long-term safety and efficacy of GDC-0853 in participants with moderate to severe active Rheumatoid Arthritis (RA) who have completed 12 weeks of study treatment in Study GA29350. Eligible participants from Study GA29350 who elect to participate will receive treatment with GDC-0853 twice daily (BID) in an open-label fashion for 52 weeks, followed by a safety follow-up period of 8 weeks.

Being tested
GDC-0853
Medical subject headings
Arthritis, Rheumatoid

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • GDC-0853Drug

    Also called RO7010939

    GDC-0853 was administered orally at a dose of 200mg, as per the dosing schedules described above.

Study groups in NCT02983227
Study groupRoleWhat they receive
GDC-0853 (200mg BID) Cohort 1ExperimentalParticipants received GDC-0853 orally twice daily (BID) for 52 weeks, after completing 12 weeks in Cohort 1 of Study GA29350. Cohort 1 participants in GA29350 were enrolled with moderate to severe active Rheumatoid Arthritis (RA) and an inadequate response to previous methotrexate (MTX) therapy and then randomized to 12 weeks of GDC-0853 (50 mg daily, 150 mg daily, or 200 mg BID), adalimumab, or placebo.
Receives: Drug: GDC-0853
GDC-0853 (200mg BID) Cohort 2ExperimentalParticipants received GDC-0853 orally twice daily (BID) for 52 weeks, after completing 12 weeks in Cohort 2 of Study GA29350. Cohort 2 participants in GA29350 were enrolled with moderate to severe active Rheumatoid Arthritis (RA) and an inadequate response to one or two tumor necrosis factor (TNF) inhibitors and methotrexate (MTX) therapy, and then randomized to 12 weeks of GDC-0853 (200 mg BID) or placebo.
Receives: Drug: GDC-0853

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Percentage of Participants With Adverse Events (AEs)

    An Adverse Event (AE) was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Preexisting conditions that worsened during the study were reported as adverse events.

    Measured: Day 1 up until 8 weeks after the last dose of study drug (up to 1 year, 2 months)

  2. Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response at Week 52

    ACR50 response is defined as a ≥ 50% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant [either C-reactive protein or Erythrocyte Sedimentation Rate].

    Measured: Week 52

Secondary outcomes (25)
  1. Percentage of Participants Achieving ACR50 Response up to Week 12

    ACR50 response is defined as a ≥ 50% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant [either C-reactive protein or Erythrocyte Sedimentation Rate].

    Measured: Weeks 4, 8 and 12

  2. Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response

    ACR20 response is defined as a ≥ 20% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant [either C-reactive protein or Erythrocyte Sedimentation Rate]

    Measured: Weeks 4, 8, 12, 24, 36 and 52

  3. Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response

    ACR70 response is defined as a ≥ 70% improvement (reduction) compared with Baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant [either C-reactive protein or Erythrocyte Sedimentation Rate].

    Measured: Weeks 4, 8, 12, 24, 36 and 52

  4. Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 CRP)

    The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) [28 joints], swollen joint count (SJC) [28 joints], patient's global assessment of disease activity [visual analog scale: 0=no disease activity to 100=maximum disease activity] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. DAS28 Remission is defined as a DAS28 score < 2.6.

    Measured: Baseline, Weeks 4, 8, 12, 24, 36 and 52

  5. Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (4 Variables) (DAS28-4 CRP)

    The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) [28 joints], swollen joint count (SJC) [28 joints], patient's global assessment of disease activity [visual analog scale: 0=no disease activity to 100=maximum disease activity] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. DAS28 Remission is defined as a DAS28 score < 2.6.

    Measured: Baseline, Weeks 4, 8, 12, 24, 36 and 52

  6. Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (3 Variables) (DAS28-3 ESR)

    The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) [28 joints], swollen joint count (SJC) [28 joints], patient's global assessment of disease activity [visual analog scale: 0=no disease activity to 100=maximum disease activity] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. DAS28 Remission is defined as a DAS28 score < 2.6.

    Measured: Baseline, Weeks 4, 8, 12, 24, 36 and 52

  7. Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 ESR)

    The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) [28 joints], swollen joint count (SJC) [28 joints], patient's global assessment of disease activity [visual analog scale: 0=no disease activity to 100=maximum disease activity] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. DAS28 Remission is defined as a DAS28 score < 2.6.

    Measured: Baseline, Weeks 4, 8, 12, 24, 36 and 52

  8. Percentage of Participants With Remission Based on Disease Activity Score Based on 28-Joints Count (DAS28)

    The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) [28 joints], swollen joint count (SJC) [28 joints], patient's global assessment of disease activity [visual analog scale: 0=no disease activity to 100=maximum disease activity] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control.

    Measured: Weeks 4, 8, 12, 24, 36 and 52

  9. Percentage of Participants With Low Disease Activity (LDA) Based on DAS28

    The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) [28 joints], swollen joint count (SJC) [28 joints], patient's global assessment of disease activity [visual analog scale: 0=no disease activity to 100=maximum disease activity] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. LDAS is defined as DAS28 ≤ 3.2

    Measured: Weeks 4, 8, 12, 24, 36 and 52

  10. Percentage of Participants With ACR/EULAR Remission

    Assessed according to the Boolean based definition (tender joint count =<1, swollen joint count =<1, C-reactive Protein (CRP) =<1, and patient global assessment =<1)

    Measured: Weeks 4, 8, 12, 24, 36 and 52

  11. Change From Baseline in Simplified Disease Activity Index (SDAI)

    Simplified Disease Activity Index (SDAI) is the numerical sum of five outcome parameters: TJC and SJC (based on a 28-joint assessment), PtGA and PhGA (based on 0-10 cm VAS, where 0 = no disease activity and 10 = worst disease activity), and CRP. SDAI total score ranges from 0 (no disease activity) to 86 (maximal disease activity), where higher scores represents higher disease activity. The SDAI =< 3.3 indicates disease remission, > 3.4 to 11 indicates low disease activity, > 11 to 26 indicates moderate disease activity, and > 26 indicates high disease activity

    Measured: Weeks 4, 8, 12, 24, 36 and 52

  12. Change From Baseline in Clinical Disease Activity Index (CDAI)

    CDAI was derived as the sum of the following: tender joint count (TJC), swollen joint count (SJC), participant global assessment (PGA) of disease activity, and physician assessment of disease activity. TJC and SJC were taken as the number of tender and swollen joints, respectively, out of 28 assessed joints. PGA and physician assessment of disease activity were scored 0-100 millimeters (mm) and rounded to the nearest centimeter (cm) on a visual analog scale (VAS), where higher scores indicate greater perceived disease activity. The total CDAI score range was 0-76, where higher scores indicate increased disease activity. Change from baseline at a particular time point was calculated among patients with data available at both baseline and the time point of interest. Negative values indicate improvement/reduction in RA disease activity.

    Measured: Weeks 4, 8, 12, 24, 36 and 52

  13. Change From Baseline in Tender/Painful Joint Count Based on 68 Joints

    Tender Joint Count: a total of 68 joints will be assessed for tenderness. Each joint is assessed for the presence/absence of tenderness. 68 joints are assessed for tenderness and joints are classified as tender/not tender giving a total possible tender joint count score of 0 to 68. A negative change from Baseline indicated improvement.

    Measured: Weeks 4, 8, 12, 24, 36 and 52

  14. Change From Baseline in Swollen Joint Count Based on 66 Joints

    Swollen Joint Count: a total of 66 joints will be assessed for swelling. Each joint is assessed for the presence/absence of swelling. 66 joints were assessed for swelling and joints are classified as swollen/not swollen giving a total possible swollen joint count score of 0 to 66. A negative change from Baseline indicated improvement.

    Measured: Weeks 4, 8, 12, 24, 36 and 52

  15. Change From Baseline in Patient's Assessment of Arthritis Pain, Using Visual Analog Scale (VAS) Score

    Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain

    Measured: Weeks 4, 8, 12, 24, 36 and 52

  16. Change From Baseline in Patient's Global Assessment of Arthritis, Using VAS Score

    Participant-assessed arthritis pain was scored on a 100-mm VAS, where the distance from 0 mm represented the participant's self evaluation of arthritis pain (0 mm=none; 100 mm=very severe). Change from baseline at a particular time point was calculated among patients with data available at both baseline and the time point of interest, where negative change indicated a decrease in participant-assessed arthritis pain.

    Measured: Weeks 4, 8, 12, 24, 36 and 52

  17. Change From Baseline in Physician's Global Assessment of Arthritis, Using VAS Score

    Physician's assessment of participant's disease activity was scored on a 100-mm VAS, where the distance from 0 mm represented the physician's assessment of the participant's disease activity (0 mm=very good; 100 mm=very poor). Change from baseline at a particular time point was calculated among patients with data available at both baseline and the time point of interest, where negative change from baseline indicated an improvement in physician-assessed disease activity.

    Measured: Weeks 4, 8, 12, 24, 36 and 52

  18. Change From Baseline in C-Reactive Protein (CRP) Levels

    C-reactive protein is a biological marker of inflammation and is measured in milligrams per decilitre (mg/dL)

    Measured: Weeks 4, 8, 12, 24, 36 and 52

  19. Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score

    The Stanford Health Assessment Questionnaire disability index is a patient-reported outcome used to assess difficulty in performing activities of daily living. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip and common daily activities.

    To respond to each question, a four-level response with higher scores showing larger functional limitations, was chosen. Scoring is as follows with respect to performance of participant's everyday activities: 0 (equals)=without difficulties; 1= with some difficulties; 2=with great difficulties; and 3=unable to perform these actions at all. The composite HAQ-DI score is the mean of the eight domain scores and the score ranges from 0 (no functional impairment) to 3 (maximum functional impairment). A negative change from baseline indicates improvement.

    Measured: Weeks 4, 8, 12, 24, 36 and 52

  20. Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Version 2.0 (V2) Scores for Physical and Mental Components

    The 36-Item Short Form Health Survey (SF-36v2) is a questionnaire used to assess functional health and well-being and consists of eight domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional and Mental Health.

    The SF-36v2 is summarized into Physical Component Summary (PCS) and Mental Component Summary (MCS) scores. The PCS and MCS scores range from 0 to 100, with 0=worst score (or quality of life) and 100=best score. A positive change from baseline indicates improvement.

    Measured: Weeks 12, 24 and 52

  21. Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score

    The FACIT-Fatigue Scale consists of 13 items designed to measure the degree of fatigue experienced by the patient in the previous 7 days. For each question, there are five possible responses: 0 (not at all), 1 (a little bit), 2 (somewhat), 3 (quite a bit), 4 (very much).

    A total fatigue score is calculated by summing all items, and possible total scores range from 0 (maximum fatigue) to 52 (no fatigue). A positive change from baseline indicates an improvement in the patient's fatigue (less fatigue).

    Measured: Weeks 12, 24 and 52

  22. Area Under the Concentration Time Curve (AUC) of GDC-0853 at Steady State (AUC,ss)

    Population PK model estimated AUC of GDC-0853 at steady-state. AUC was measured in Nanograms (ng) per millilitre(mL)*hour (hr).

    Measured: Pre-dose (0 hour) on Weeks 0 (Day 1), 4, 12, 24, 36, and 52/early termination

  23. Minimum Plasma Concentration of GDC-0853 at Steady State (Ctrough,ss)

    Population PK model estimated minimal plasma concentration (Ctrough) of GDC-0853 at steady-state (ss).

    Measured: Pre-dose (0 hour) on Weeks 0 (Day 1), 4, 12, 24, 36, and 52/early termination

  24. Plasma Decay Half-Life of GDC-0853 at Steady State (t1/2,ss)

    Population PK model estimated plasma decay half life of GDC-0853 at steady-state.

    Measured: Pre-dose (0 hour) on Weeks 0 (Day 1), 4, 12, 24, 36, and 52/early termination

  25. Apparent Oral Clearance of GDC-0853 at Steady State (CL/F,ss)

    Population PK model estimated apparent oral clearance of GDC-0853 at steady-state.

    Measured: Pre-dose (0 hour) on Weeks 0 (Day 1), 4, 12, 24, 36, and 52/early termination

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 Dec 2016 (estimated)
  2. Study start30 Nov 2016
  3. Primary completion17 Jul 2019
  4. Study completion17 Jul 2019

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
496 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02983227
Sponsor's protocol ID
GA30067
Other IDs
2016-000498-19, 2016
Status last verified
Jul 2020
First submitted
29 Nov 2016
Last updated
3 Aug 2020
FDA-regulated drug
Yes
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing GDC-0853 in people with Rheumatoid Arthritis, run by Genentech, Inc. at 104 sites in 10 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 3 Aug 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 104 sites in Ukraine, Russia, United States, Argentina, Bulgaria and 5 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 3 Aug 2020). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percentage of Participants With Adverse Events (AEs) (time frame: Day 1 up until 8 weeks after the last dose of study drug (up to 1 year, 2 months)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Aug 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in